VWF and thrombotic thrombocytopenic purpura: From a clinical perspective, it is promising that the first-generation of VWF-inhibitors is currently enrolled in clinical studies for thrombotic thrombocytopenic purpura, such as a specific inhibitor of the VWF-GPIbα interaction (79) and recombinant ADAMTS13 (80).